Haven't followed the stock for a long time. I stumbled across...

Haven't followed the stock for a long time. I stumbled across the stock today, surprised to find this company is still ASX-listed after withdrawing Axiron.

Anyone care to shed lights on how superior is Jublia cf the competitors. From my understanding, it is just antifungal topical solutions similar to the Daktarin Tincture in Australia, which has a lower success rate cf other antifungal Loceryl, Canesten & Revujenail. Not to say there are also non-medicated treatment available now, eg Excilor, Emtrix and Scholl.

From my pharmacy experience, Daktarin Tincture doesn't sell well and generally only sold to Aboriginals on PBS-subsidized prescriptions. I can't see why would Jublia succeed in Onchomychosis market, let alone its generic version.

I haven't researched the US treatment guideline for onchomycosis, but I highly doubt there aren't any better treatment than Jublia.

DYOR